DE69727314D1 - Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix) - Google Patents

Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix)

Info

Publication number
DE69727314D1
DE69727314D1 DE69727314T DE69727314T DE69727314D1 DE 69727314 D1 DE69727314 D1 DE 69727314D1 DE 69727314 T DE69727314 T DE 69727314T DE 69727314 T DE69727314 T DE 69727314T DE 69727314 D1 DE69727314 D1 DE 69727314D1
Authority
DE
Germany
Prior art keywords
iscom
matrix
stimulating complex
pct
immun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727314T
Other languages
English (en)
Other versions
DE69727314T2 (de
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69727314D1 publication Critical patent/DE69727314D1/de
Application granted granted Critical
Publication of DE69727314T2 publication Critical patent/DE69727314T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
DE1997627314 1996-02-21 1997-02-20 Ein ISCOM oder eine ISCOM-Matrix, umfassend hydrophobe Rezeptormoleküle für antigene Stoffe Expired - Lifetime DE69727314T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9600648 1996-02-21
SE9600648A SE9600648D0 (sv) 1996-02-21 1996-02-21 Receptorbimdande enhet
PCT/SE1997/000287 WO1997030726A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances

Publications (2)

Publication Number Publication Date
DE69727314D1 true DE69727314D1 (de) 2004-02-26
DE69727314T2 DE69727314T2 (de) 2004-11-18

Family

ID=20401482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1997627314 Expired - Lifetime DE69727314T2 (de) 1996-02-21 1997-02-20 Ein ISCOM oder eine ISCOM-Matrix, umfassend hydrophobe Rezeptormoleküle für antigene Stoffe

Country Status (12)

Country Link
US (1) US6027732A (de)
EP (1) EP0944397B1 (de)
AT (1) ATE258066T1 (de)
AU (1) AU718443B2 (de)
BR (1) BR9707638A (de)
CA (1) CA2247103C (de)
DE (1) DE69727314T2 (de)
DK (1) DK0944397T3 (de)
ES (1) ES2214608T3 (de)
NZ (1) NZ331418A (de)
SE (1) SE9600648D0 (de)
WO (1) WO1997030726A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DK2204186T3 (en) * 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
WO2003059380A2 (de) * 2002-01-15 2003-07-24 Bio Life Science Forschungs Und Entwicklungsges M.B.H. Orale vakzinierung
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
BR112016015422A2 (pt) 2013-12-31 2017-10-24 Infectious Disease Res Inst formulações de vacina de frasco único
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.

Also Published As

Publication number Publication date
NZ331418A (en) 2000-03-27
EP0944397B1 (de) 2004-01-21
US6027732A (en) 2000-02-22
AU718443B2 (en) 2000-04-13
ATE258066T1 (de) 2004-02-15
AU2238397A (en) 1997-09-10
EP0944397A1 (de) 1999-09-29
ES2214608T3 (es) 2004-09-16
CA2247103C (en) 2009-01-20
SE9600648D0 (sv) 1996-02-21
DE69727314T2 (de) 2004-11-18
DK0944397T3 (da) 2004-06-01
WO1997030726A1 (en) 1997-08-28
CA2247103A1 (en) 1997-08-28
BR9707638A (pt) 2000-01-04

Similar Documents

Publication Publication Date Title
DE69727314D1 (de) Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix)
TR199800812T2 (xx) Uzun-dayanan kozmetik �r�nlerinin performans�n�n geli�tirilmesi i�in y�ntemler ve bile�imler.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CL2012001063A1 (es) Anticuerpo humano que se une a interleuquina 18 humana (il-18h), metodo de preparacion, acidos nucleicos que lo dosifican, composicion que los contiene, uso en la preparacion de un medicamento para tratar patologias mediadas por il-18h. (divisional sol. 316-01).
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DE69919692D1 (de) Verabreichungssystem für Impstoffe basierend auf Gonokokkenblebosomen
ATE360032T1 (de) Cystein-reiche rezeptoren-train
TR200102041T2 (tr) Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar
DE69120942T2 (de) Hilfsstoffzusammensetzungen in fester form, dispergieren in wässerigen medien
SE0303476D0 (sv) Device, method and use for the formation of small particles
ATE160839T1 (de) Ausfachsystem für wände und verkleidungen im bauwesen
TR199902585T2 (xx) Elyafl� par�ac�klar�n franksiyonlanmas� ve da��t�lmas�na mahsus tertibat.
ID21353A (id) Senyawa bi-aromatik yang terikat melalui radikal heteroetilena, serta komposisi farmasi dan kosmetik yang mengandungnya
GB9811221D0 (en) Bacterial-pheromones and uses therefor
ATE145191T1 (de) Azofarbstoffe enthaltende molekularsiebe
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
BG101114A (en) New amidoquinoxalindions, their preparation and application
UA29496C2 (uk) Ротор для перемішуючих пристроїв
Harlan VizieR Online Data Catalog: MK Classifications for F-and G-type stars (Harlan, 1969-1981)
ES2116946B1 (es) Composicion para la obtencion de un aguardiente.
ATE279207T1 (de) Spezifischer immunstimulierender factor mit hoher fluoreszens und verfahren für dessen verwendung
Hopp et al. VizieR Online Data Catalog: CCD photometry of 11 dwarf irregular galaxies (Hopp+, 1995)
Davoust et al. VizieR Online Data Catalog: Bibliography of Surface Photometry of galaxies (Davoust+ 1982)
Turner et al. VizieR Online Data Catalog: Tests of shock chemistry in IC 443G (Turner+, 1992)
BR0204948A (pt) Misturas de tintas bisazo fibra-reativas e uso das mesmas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition